Cempra Inc  

(Public, NASDAQ:CEMP)   Watch this stock  
Find more results for CEMP
2.92
-0.12 (-4.10%)
After Hours: 2.90 -0.03 (-1.03%)
Oct 18, 7:02PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.90 - 3.05
52 week 2.55 - 24.48
Open 3.00
Vol / Avg. 521,027.00/949,823.00
Mkt cap 153.58M
P/E     -
Div/yield     -
EPS -1.89
Shares 52.51M
Beta 1.12
Inst. own 61%
Nov 3, 2017
Cempra Inc Annual Shareholders Meeting - 8:00AM EDT - Add to calendar
Oct 25, 2017
Q3 2017 Cempra Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 26, 2017
Cempra Inc at Ladenburg Thalmann Healthcare Conference
Sep 12, 2017
Cempra Inc at Morgan Stanley Healthcare Conference - Webcast
Aug 9, 2017
Q2 2017 Cempra Inc Earnings Release
Aug 9, 2017
Q2 2017 Cempra Inc Earnings and Update on the Merger with Melinta Therapeutics Inc Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -1426.39% -654.76%
Operating margin -1435.35% -650.58%
EBITD margin - -650.29%
Return on average assets -24.54% -58.88%
Return on average equity -31.22% -78.38%
Employees 45 -
CDP Score - -

Address

6320 Quadrangle Dr Ste 360
CHAPEL HILL, NC 27517-7890
United States - Map
+1-919-5762306 (Phone)
+1-302-5313150 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cempra, Inc. is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP). Solithromycin has therapeutic potential and activity to target pathogenic bacteria. It has completed two pivotal Phase III trials for solithromycin to treat CABP, as of December 31, 2016. Its Fusidic acid is an antibiotic and the Company is exploring its use for the long-term oral treatment for refractory bone and joint infections (BJI), including prosthetic joint infections, which are caused by staphylococci, including S. aureus, methicillin-resistant S. aureus, coagulase negative staphylococci and other gram-positive bacteria.

Officers and directors

Garheng Kong M.D. Ph.D. Independent Chairman of the Board
Age: 41
Bio & Compensation  - Reuters
David Zaccardelli Pharm.D. Acting Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Mark W. Hahn Chief Financial Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
John D Bluth Executive Vice President - Investor Relations and Corporate Communications
Bio & Compensation  - Reuters
David William Oldach Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters
Michael R. Dougherty Independent Director
Age: 58
Bio & Compensation  - Reuters
David N. Gill Independent Director
Age: 62
Bio & Compensation  - Reuters
Dov A. Goldstein M.D. Independent Director
Age: 49
Bio & Compensation  - Reuters
John H. Johnson Independent Director
Age: 59
Bio & Compensation  - Reuters
Richard S. Kent M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters